Proprietary decapeptide drugs developed for tumor therapy of steroidal cancers (breast/mamma, ovarial, endometrial, prostate) and malignant melanoma. Mono-therapy or combi-therapy with current drugs possible due to huge synergism. Resensitization of tamoxifen resistant tumors and therapy of triple-negative breast cancer.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
